Form 4: Silo Pharma CEO Eric Weisblum Reports Stock Purchases
SEC Form 4 Filing
Silo Pharma's CEO, Eric Weisblum, reported purchasing common stock in the company on April 4th and 5th, 2024.
Summary
- Eric Weisblum, CEO and President of Silo Pharma, Inc., filed a Form 4 with the SEC.
- The form reports purchases of common stock on April 4, 2024, and April 5, 2024.
- On April 4, 2024, 600 shares were purchased at a weighted average price of $1.96.
- On April 5, 2024, 400 shares were purchased at a weighted average price of $2.03.
- Following these transactions, Weisblum directly owns 175,432 shares of Silo Pharma, Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a report of stock purchases, neither overtly positive nor negative.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 04/04/2024 | Purchase of 600 shares of common stock at a weighted average price of $1.96. |
| 04/05/2024 | Purchase of 400 shares of common stock at a weighted average price of $2.03. |
| 04/08/2024 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Silo Pharma, Eric Weisblum, Stock Purchase, Beneficial Ownership, SILO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.